enteroviru
emerg
clinic
import
neurotrop
viru
caus
acut
flaccid
paralysi
enceph
lead
cardiopulmonari
failur
death
recur
outbreak
report
sever
countri
current
lack
approv
therapi
prompt
intens
research
antivir
develop
sever
strategi
rang
targetbas
chemic
design
compound
librari
screen
employ
other
revisit
compound
seri
gener
antivir
develop
polioviru
human
rhinovirus
effort
given
rise
divers
antivir
candid
includ
small
molecul
nonconvent
nucleicacidbas
strategi
review
aim
highlight
candid
potenti
clinic
develop
base
put
mode
action
enteroviru
describ
one
human
enteroviru
speci
genu
enteroviru
picornavirida
famili
virus
includ
polioviru
effort
erad
polioviru
vaccin
program
limit
number
polioendem
countri
four
afghanistan
india
nigeria
pakistan
emerg
import
nonpolio
neurotrop
enteroviru
first
isol
patient
central
nervou
system
diseas
california
author
also
describ
prototyp
strain
brcr
isol
twomonthold
patient
present
asept
mening
sinc
outbreak
report
sever
countri
beyond
north
america
includ
taiwan
australia
malaysia
singapor
outbreak
mainli
involv
young
children
case
display
mild
selflimit
hand
foot
mouth
diseas
howev
outbreak
also
associ
varieti
sever
neurolog
complic
deterior
rapidli
involv
cardiopulmonari
failur
high
mortal
rate
transmiss
occur
rapidli
via
fecalor
droplet
andor
aerosol
rout
largest
outbreak
date
taiwan
children
affect
sever
case
involv
neurolog
cardiopulmonari
complic
fatal
spectrum
neurolog
diseas
includ
asept
mening
brain
stem
enceph
poliomyelitislik
acut
flaccid
paralysi
like
poliomyel
sever
infect
result
perman
neurolog
damag
longterm
studi
children
surviv
neurolog
involv
infect
outbreak
taiwan
patient
sever
infect
involv
neurolog
cardiopulmonari
complic
display
sign
neurolog
sequela
impair
neurodevelop
impair
cognit
function
current
effect
vaccin
antivir
treatment
acut
infect
neurolog
manifest
mainli
aim
allevi
symptom
mechan
cardiopulmonari
support
system
administr
milrinon
posit
inotrop
agent
use
prevent
cardiopulmonari
failur
thu
improv
clinic
outcom
patient
lack
antivir
treatment
option
remain
worri
situat
howev
found
circul
endem
peak
activ
warmer
season
eg
summer
fall
consid
propens
caus
sever
neurolog
diseas
children
need
develop
effect
antivir
treatment
option
prevent
reduc
death
longterm
neuropathi
next
global
outbreak
review
focu
document
recent
develop
toward
antivir
infect
previou
review
cover
develop
antivir
target
picornavirus
enterovirus
gener
howev
except
polioviru
distinguish
enterovirus
term
circul
sever
associ
diseas
contrast
polioviru
highli
effect
vaccin
avail
global
popul
remain
larg
unprotect
review
therefor
highlight
promis
strategi
put
mode
inhibit
understand
molecular
mechan
viral
infect
replic
enabl
identif
potenti
antivir
target
although
exact
mechan
replic
elucid
picornavirus
gener
share
highli
similar
viru
architectur
mode
replic
picornavirus
nonenvelop
virus
nm
diamet
icosahedr
capsid
made
protom
turn
made
four
structur
protein
picornaviru
genom
encod
singlestrand
positivesens
rna
base
consist
open
read
frame
flank
untransl
region
utr
upon
viru
attach
entri
host
cell
uncap
event
occur
releas
rna
genom
cell
coval
attach
end
viral
protein
vpg
cleav
cellular
enzym
earli
infect
wherea
end
poli
tract
utr
highli
structur
region
interact
varieti
viral
host
protein
translat
rna
synthesi
event
capindepend
translat
viral
rna
take
place
recruit
host
replic
machineri
intern
ribosom
entri
site
locat
utr
viral
rna
viral
polyprotein
divid
three
precursor
molecul
fig
contain
viral
capsid
protein
carri
viral
nonstructur
protein
function
viral
protein
precursor
protein
produc
upon
matur
cleavag
polyprotein
virusencod
proteas
pro
pro
neg
rna
intermedi
graphic
overview
picornaviru
replic
viru
particl
first
attach
host
cell
surfac
via
cellular
receptor
enter
uncoat
unveil
viral
rna
genom
viral
rna
translat
cellular
translat
machineri
give
polyprotein
cleav
virusencod
proteas
pro
pro
give
function
precursor
protein
eg
individu
protein
within
virusinduc
membran
vesicl
viral
rna
copi
viral
rna
polymeras
pol
give
strand
rna
intermedi
turn
provid
templat
synthesi
strand
viral
rna
strand
viral
rna
use
gener
strand
viral
rna
translat
viral
protein
packag
progeni
virion
lysi
host
cell
result
releas
progeni
virion
adapt
modifi
figur
ref
figur
ref
viral
genom
also
gener
serv
templat
replic
positivesens
rna
viral
genom
event
typic
take
place
virusinduc
membran
complex
within
host
cell
progeni
virion
selfassembl
synthes
viral
protein
rna
genom
subsequ
releas
host
cell
fig
receptor
bind
essenti
event
viru
infect
abil
recogn
bind
specif
receptor
typic
determin
host
rang
tissu
tropism
virus
recent
character
receptor
open
door
develop
antivir
strategi
target
entri
host
cell
least
three
cellular
receptor
report
date
human
scaveng
receptor
class
b
member
describ
receptor
strain
three
genogroup
b
c
type
iii
doubletransmembran
protein
primarili
locat
endosom
although
surfac
express
also
demonstr
second
receptor
human
pselectin
glycoprotein
sialomucin
membran
protein
express
mainli
leukocyt
includ
dendrit
cell
macrophag
postul
facilit
virem
phase
enabl
replic
circul
leukocyt
use
monoclon
antibodi
target
differ
part
author
identifi
ntermin
region
crucial
interact
site
sialic
acid
residu
might
also
import
interact
studi
yang
et
al
sialidas
remov
sialic
acid
residu
plasma
membran
protein
abl
protect
intestin
cell
infect
anoth
studi
found
infect
immatur
dendrit
cell
via
dcsign
infect
reduc
antidcsign
antibodi
use
block
dcsign
potenti
develop
antivir
strategi
target
receptor
bind
demonstr
studi
antibodi
solubl
conjug
abl
inhibit
infect
dosedepend
manner
likewis
solubl
monoclon
antibodi
target
ntermin
sialyl
glycan
purifi
human
milk
display
dosedepend
inhibit
coinfect
pretreat
experi
unfortun
unabl
inhibit
infect
complet
highest
concentr
test
suggest
involv
multipl
receptor
infect
address
futur
combin
administr
inhibitor
target
differ
receptor
potenti
discoveri
receptor
futur
particular
neuralspecif
receptor
might
eventu
lead
develop
effect
receptor
inhibitor
prevent
neuropatholog
hydrophob
pocket
within
viral
protein
wellknown
target
antivir
design
occup
suitabl
compound
stabil
viru
capsid
prevent
uncoat
viru
rna
releas
promin
seri
capsidbind
compound
includ
win
seri
sterlingwinthrop
eg
pleconaril
sch
seri
schere
plough
eg
sch
r
compound
janssen
research
foundat
eg
pirodavir
although
antivir
activ
claim
broad
spectrum
picornavirus
notabl
absent
list
picornavirus
test
studi
characterist
clinic
develop
picornaviru
capsidbind
molecul
detail
sever
comprehens
review
taiwan
outbreak
pleconaril
test
fail
prevent
virusinduc
cytopath
effect
cell
cultur
view
emerg
clinic
import
picornaviru
need
reevalu
compound
use
win
compound
templat
seri
imidazolidon
deriv
design
comput
model
synthes
evalu
abil
inhibit
cytopath
effect
rhabdomyosarcoma
rd
cell
sever
lead
molecul
strong
inhibit
three
genogroup
ec
mm
low
cytotox
cc
mm
discov
seri
public
group
later
document
variou
chemic
modif
improv
antivir
activ
includ
substitut
phenoxyl
group
ec
mm
oxim
ether
group
addit
ec
mm
methyl
group
addit
ec
mm
compound
evalu
activ
murin
model
promis
result
although
current
lack
fund
imped
progress
clinic
trial
sr
shih
per
commun
oximeeth
deriv
pirodavir
display
improv
metabol
stabil
antivir
activ
greater
spectrum
picornavirus
rel
pirodavir
notabl
one
compound
inhibit
ec
mm
report
cc
mm
bovin
lactoferrin
human
lactoferrin
found
inhibit
infect
rd
cell
earli
stage
infect
mean
ec
mgml
mgml
respect
bovin
lactoferrin
delay
paralysi
death
two
week
postinfect
mice
coinject
interact
assay
use
conjug
antibodi
demonstr
direct
bind
lactoferrin
cell
surfac
suggest
lactoferrin
role
prevent
viru
attach
block
cellular
receptor
andor
receptorinteract
site
exact
antivir
mechan
lactoferrin
remain
determin
howev
potenc
earli
inhibitor
led
author
studi
propos
investig
ingest
milk
prophylaxi
suramin
polysulfon
shown
effect
inhibitor
hiv
replic
infect
patient
polysulfon
known
multitarget
inhibitor
hiv
viral
target
includ
revers
transcriptas
viral
envelop
glycoprotein
suramin
analog
carbonylbi
carbonylimino
acid
identifi
earli
inhibitor
infect
viru
uncoat
host
receptor
bind
ec
mm
cc
mm
screen
compound
drug
librari
sigmaaldrich
strain
isol
studi
display
mutat
viral
capsid
protein
suggest
put
target
translat
viral
rna
next
key
step
viru
replic
viru
essenti
use
cellular
machineri
protein
translat
import
develop
antivir
strategi
inhibit
viral
protein
synthesi
without
affect
host
cell
translat
event
current
report
viralspecif
smallmolecul
inhibitor
protein
synthesi
activ
amantadin
found
inhibit
capindepend
translat
initi
intern
ribosom
entri
site
bicistron
report
system
although
direct
antivir
activ
verifi
promis
nonconvent
antivir
approach
target
viral
rna
translat
might
rna
interfer
rnai
potenti
nucleicacidbas
therapi
seen
fda
approv
fomivirsen
vitraven
use
cytomegaloviru
retin
mani
rnaibas
antivir
therapeut
current
undergo
variou
phase
clinic
trial
virus
respiratori
syncyti
viru
hepat
c
viru
sever
highli
conserv
sequenc
identifi
target
rnai
genom
small
interf
rna
sirna
plasmidencod
short
hairpin
rna
shrna
found
effect
block
replic
target
utr
region
encod
structur
protein
eg
nonstructur
protein
eg
two
studi
report
greatest
inhibitori
effect
target
viral
rna
polymeras
sirna
plasmidencod
shrna
target
abl
prevent
paralysi
weight
loss
death
suckl
mice
deliv
via
oral
intraperiton
rout
author
also
observ
similar
antivir
effect
nucleotid
deliv
without
lipid
carrier
promis
preclin
result
follow
clinic
trial
rnabas
therapeut
asid
role
matur
cleavag
viral
polyprotein
proteas
also
target
sever
host
protein
eukaryot
translat
initi
factor
cleavag
stimul
factor
halt
host
protein
synthesi
induc
apoptosi
essenti
role
proteas
viru
replic
make
attract
target
antivir
therapeut
sever
peptid
aldehyd
design
irrevers
inhibit
human
rhinoviru
hrv
pro
form
coval
adduct
review
ref
one
compound
rupintrivir
pfizer
reach
phase
ii
clinic
trial
studi
ceas
display
poor
efficaci
natur
infect
case
hrv
kuo
et
al
develop
seri
compound
base
rupintrivir
test
pro
vitro
compound
identifi
potent
inhibitor
ec
mm
show
toxic
cc
mm
studi
need
evalu
compound
efficaci
vivo
recent
rupintrivir
shown
inhibit
ec
mm
use
realtim
cellbas
fluoresc
reson
energi
transfer
assay
plaqu
reduct
assay
compound
oral
bioavail
pro
inhibitor
develop
parallel
rupintrivir
also
show
vitro
antivir
properti
sever
human
enterovirus
also
evalu
properti
highli
conserv
picornaviru
protein
multifunct
protein
possess
nucleosid
triphosphatas
activ
shown
involv
synthesi
viral
negativestrand
rna
encapsid
progeni
virion
polioviru
protein
report
recruit
hostencod
reticulon
form
replic
complex
metrifudil
n
methyladenosin
n
benzyladenosin
identifi
inhibitor
screen
inhibitor
viru
attach
entri
uncoat
report
ec
mm
metrifudil
mm
n
benzyladenosin
deriv
pseudoviru
structur
gene
replac
firefli
luciferas
gene
metrifudil
n
benzyladenosin
adenosin
receptor
agonist
also
show
low
cytotox
cc
mm
mm
respect
author
manag
isol
drugresist
mutat
protein
three
passag
thu
suggest
nonconserv
region
probabl
target
compound
picornaviru
protein
essenti
multifunct
protein
shown
modul
host
cell
intracellular
membran
transport
protein
function
primarili
precursor
form
rnabind
properti
known
stimul
cleavag
pro
activ
rna
polymeras
pol
enviroxim
benzimidazol
deriv
inhibit
rhinovirus
polioviru
vitro
target
protein
recent
enviroxim
report
strong
antivir
effect
ec
mm
enviroxim
howev
unabl
show
signific
clinic
effect
p
poor
bioavail
gastrointestin
sideeffect
observ
trial
subject
vinlyacetylen
analog
enviroxim
report
display
better
oral
bioavail
retain
protein
target
antivir
activ
polioviru
therefor
evalu
activ
tabl
scholar
report
sever
function
analog
enviroxim
also
target
protein
inhibitor
identifi
inhibitor
drug
librari
screen
describ
previous
metrifudil
inhibitor
protein
found
cc
mm
inhibit
pseudoviru
ec
mm
postinfect
addit
mm
also
show
fold
inhibit
target
identifi
later
studi
found
region
target
enviroxim
protein
current
evalu
vivo
activ
murin
model
arita
per
commun
picornaviru
rna
polymeras
involv
sever
crucial
replic
event
besid
incorpor
nucleotid
synthesi
neg
posit
viral
rna
strand
studi
shown
pol
respons
uridyl
vpg
confer
prime
function
vpg
rna
replic
viral
protein
precursor
form
pol
also
involv
polyprotein
process
promot
rna
synthesi
bind
cloverleaf
structur
viral
rna
synthet
compound
seri
piperazinecontain
pyrazolo
pyrimidin
deriv
identifi
novel
class
compound
activ
compound
evalu
ec
mm
strain
genotyp
cc
greater
mm
found
suppress
synthesi
posit
neg
strand
viral
rna
infect
subsequ
analys
resist
virus
identifi
target
rna
polymeras
pol
aurintricarboxyl
acid
ata
polyanion
compound
broadspectrum
antivir
activ
report
varieti
virus
eg
hiv
sever
acut
respiratori
syndrom
coronaviru
recent
report
potent
inhibitor
plaqu
reduct
assay
deriv
ec
mm
display
low
cytotox
african
green
monkey
kidney
vero
cell
cc
mm
author
manag
rule
ata
target
viral
adsorpt
viral
rna
translat
viral
proteas
pro
pro
observ
ata
inhibit
rna
elong
pol
ribavirin
broadspectrum
antivir
use
treat
hepat
c
viru
infect
combin
interferona
sever
respiratori
syncyti
viru
infect
studi
shown
main
antivir
mechan
ribavirin
lethal
mutagenesi
virus
rna
replic
event
ribavirin
found
inhibit
rd
cell
ec
mgml
mm
prevent
paralysi
death
mice
continu
progress
antivir
develop
ribavirin
might
prove
clinic
use
infect
futur
use
lower
concentr
combin
antivir
epigallocatechin
gallat
polyphenol
compound
isol
green
tea
leav
camellia
sinensi
test
antivir
properti
epigallocatechin
gallat
egcg
found
potent
compound
postinfect
addit
mm
egcg
result
reduct
plaqu
format
cytopath
effect
reduc
twofold
viral
rna
level
significantli
decreas
p
treat
vs
control
egcg
potenc
agent
among
polyphenol
test
correl
high
antioxid
capac
infect
observ
result
increas
oxid
stress
cell
defici
dehydrogenas
support
effici
replic
associ
cellular
redox
statu
replic
led
author
suggest
egcg
inhibit
replic
modul
oxid
stress
howev
remain
unclear
whether
associ
repres
direct
causal
relationship
egcg
inhibit
induct
type
interferon
ifn
eg
interferonab
earli
nonspecif
host
immun
respons
viral
infect
lead
induct
antivir
mechan
inject
mg
polyriboinosin
polyribocytidyl
acid
poli
c
potent
ifn
induc
mice
hour
inocul
result
increas
serum
level
ifna
improv
surviv
rate
significantli
decreas
tissu
viral
load
p
treat
vs
control
mortal
aloeemodin
aloeemodin
plantderiv
anthraquinon
deriv
abl
induc
increas
ifna
express
human
medullablastoma
cell
show
low
toxic
human
promonocyt
hlcz
cell
line
cc
mgml
mgml
respect
pretreat
cell
cell
line
aloeemodin
result
lower
plaqu
format
infect
ec
mgml
mgml
respect
result
high
therapeut
index
cc
ec
valu
aloeemodin
suggest
therapeut
potenti
compound
chloroquin
use
inhibitor
viru
uncoat
studi
apoptosi
wherebi
experi
design
investig
chloroquin
characterist
nonetheless
treatment
mm
chloroquin
result
fold
reduct
rna
synthesi
antimalari
drug
chloroquin
gain
interest
potent
antivir
drug
studi
show
antivir
activ
divers
virus
sever
acut
respiratori
syndrom
coronaviru
hiv
investig
inhibitori
mechan
chloroquin
virus
show
varieti
target
process
involv
given
vari
antivir
pathway
chloroquin
author
claim
uncoat
inhibit
verifi
experi
howev
experi
use
chloroquin
malaria
treatment
wide
avail
add
appeal
investig
potenti
allophycocyanin
allophycocyanin
red
fluoresc
protein
purifi
marin
alga
spirulina
platensi
found
prevent
apoptosi
delay
viral
rna
synthesi
reduc
plaqu
format
ec
mm
cc
mm
postinfect
experi
vero
cell
specif
target
inhibit
allophycocyanin
current
unknown
raoulic
acid
raoulic
acid
purifi
wholepl
extract
new
zealand
plant
raoulia
australi
test
antivir
activ
wide
rang
virus
cc
mg
ml
vero
cell
abl
inhibit
ec
less
mgml
give
therapeut
index
greater
drug
treatment
perform
postinfect
target
inhibit
investig
studi
ursol
acid
ursol
acid
triterpenoid
purifi
water
extract
ocimum
basilicum
herb
commonli
use
tradit
chines
medicin
ursol
acid
show
low
cytotox
hep
hepatoblastomaderiv
cell
cc
mgml
inhibit
cytopath
effect
ec
mgml
timeofaddit
studi
reveal
postinfect
inhibit
lower
dose
ursol
acid
test
mgml
although
exact
mechan
inhibit
remain
unclear
antivir
agent
literatur
preliminari
stage
develop
ie
vitro
studi
promis
candid
select
base
antivir
potenc
cytotox
profil
among
compound
mention
review
approv
clinic
use
diseas
eg
chloroquin
gener
nontox
eg
lactoferrin
attract
candid
evalu
vivo
clinic
trial
earlier
effort
develop
antivir
agent
hrv
polioviru
yield
compound
seri
antipicornavir
activ
research
seri
howev
seem
ceas
highli
success
implement
oral
polio
vaccin
compound
might
still
prove
use
agent
lead
molecul
design
effect
agent
exemplifi
develop
capsid
binder
evalu
current
strain
fact
extens
pharmacokinet
character
variou
stage
clinic
trial
compound
pleconaril
capsid
binder
rupintrivir
pro
inhibitor
enviroxim
inhibitor
serv
inform
futur
develop
agent
mechan
behind
neuropathogenesi
infect
current
unknown
sever
theori
propos
includ
host
immunemedi
inflamm
central
nervou
system
cn
neural
apoptot
cell
death
infect
spread
cn
murin
studi
report
retrograd
axon
transport
major
transmiss
rout
neuroinvas
contrast
hematogen
transmiss
viru
cross
bloodbrain
barrier
skelet
muscl
found
serv
import
site
viral
replic
entri
cn
via
peripher
nerv
innerv
infect
site
fatal
infect
case
patient
usual
present
three
five
day
fever
headach
oral
ulcer
vesicular
rash
hand
foot
buttock
test
posit
rapid
deterior
sever
diseas
lag
time
primari
infect
sever
neural
diseas
might
prove
import
window
opportun
antivir
intervent
although
neuropathogenesi
would
argu
system
antivir
cross
bloodbrain
barrier
rout
administr
might
also
prove
use
prevent
neuroinvas
transmiss
inhibit
replic
site
infect
eg
skelet
muscl
gastrointestin
line
vesicular
rash
skin
antivir
prophylact
avail
sever
infect
avail
antivir
option
consid
pend
futur
progress
understand
diseas
progress
infect
futur
report
vivo
efficaci
pharmacokinet
antivir
candid
effect
antivir
essenti
tool
nullifi
grow
threat
neurotop
viru
even
search
vaccin
continu
develop
antivir
agent
remain
pertin
seen
case
polioviru
lack
antivir
option
prevent
complet
erad
polio
